Comprehensive microRNA Analysis Identifies miR-24 and miR-125a-5p as Plasma Biomarkers for Rheumatoid Arthritis

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Murata, Koichi ^a   Furu, Moritoshi ^a   Yoshitomi, Hiroyuki ^a   Ishikawa, Masahiro ^a   Shibuya, Hideyuki ^a   Hashimoto, Motomu ^a   Imura, Yoshitaka ^a   Fujii, Takao ^a   Ito, Hiromu ^a   Mimori, Tsuneyo ^a   Matsuda, Shuichi ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; MICRORNA; MICRORNA 125A-5P; MICRORNA 24; MICRORNA 26A; MICRORNA 30A-5P; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; HUMANS; LOGISTIC MODELS; MICRORNAS; REAL-TIME POLYMERASE CHAIN REACTION; ROC CURVE;

EID: 84880424761     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069118     Document Type: Article

References (62)

1. Lee DM, Weinblatt ME, (2001) Rheumatoid arthritis. Lancet 358: 903-911.
2. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, et al. (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52: 3381-3390.
3. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, et al. (2006) A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54: 26-37.
4. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, et al. (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62: 2569-2581.
5. Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, et al. (2012) Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 106: 768-774.
6. Bartel DP, (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
7. Wu L, Fan J, Belasco JG, (2006) MicroRNAs direct rapid deadenylation of mRNA. Proc Natl Acad Sci U S A 103: 4034-4039.
8. Behm-Ansmant I, Rehwinkel J, Doerks T, Stark A, Bork P, et al. (2006) mRNA degradation by miRNAs and GW182 requires both CCR4:NOT deadenylase and DCP1:DCP2 decapping complexes. Genes Dev 20: 1885-1898.
9. Kozomara A, Griffiths-Jones S, (2011) miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 39: D152-D157.
10. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, et al. (2006) miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 3: 87-98.
11. He L, He X, Lowe SW, Hannon GJ, (2007) microRNAs join the p53 network-another piece in the tumour-suppression puzzle. Nat Rev Cancer 7: 819-822.
12. Chen CZ, Li L, Lodish HF, Bartel DP, (2004) MicroRNAs modulate hematopoietic lineage differentiation. Science 303: 83-86.
13. Callis TE, Chen JF, Wang DZ, (2007) MicroRNAs in skeletal and cardiac muscle development. DNA Cell Biol 26: 219-225.
14. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, et al. (2007) MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297: 1901-1908.
15. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, et al. (2008) MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299: 425-436.
16. Lewis BP, Burge CB, Bartel DP, (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20.
17. Filkova M, Jungel A, Gay RE, Gay S, (2012) MicroRNAs in rheumatoid arthritis: potential role in diagnosis and therapy. BioDrugs 26: 131-141.
18. Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, et al. (2008) Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther 10: R101.
19. Niimoto T, Nakasa T, Ishikawa M, Okuhara A, Izumi B, et al. (2010) MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients. BMC Musculoskelet Disord 11: 209.
20. Stanczyk J, Pedrioli DM, Brentano F, Sanchez-Pernaute O, Kolling C, et al. (2008) Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum 58: 1001-1009.
21. Stanczyk J, Ospelt C, Karouzakis E, Filer A, Raza K, et al. (2011) Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis Rheum 63: 373-381.
22. Nakamachi Y, Kawano S, Takenokuchi M, Nishimura K, Sakai Y, et al. (2009) MicroRNA-124a is a key regulator of proliferation and monocyte chemoattractant protein 1 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum 60: 1294-1304.
23. Nakasa T, Shibuya H, Nagata Y, Niimoto T, Ochi M, (2011) The inhibitory effect of microRNA-146a expression on bone destruction in collagen-induced arthritis. Arthritis Rheum 63: 1582-1590.
24. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105: 10513-10518.
25. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, et al. (2010) The microRNA spectrum in 12 body fluids. Clin Chem 56: 1733-1741.
26. Murata K, Yoshitomi H, Tanida S, Ishikawa M, Nishitani K, et al. (2010) Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 12: R86.
27. Liu H, Zhu L, Liu B, Yang L, Meng X, et al. (2012) Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett 316: 196-203.
28. Schrauder MG, Strick R, Schulz-Wendtland R, Strissel PL, Kahmann L, et al. (2012) Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One 7: e29770.
29. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324.
30. Altman R, Asch E, Bloch D, Bole G, Borenstein D, et al. (1986) Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 29: 1039-1049.
31. Hochberg MC, (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 1725.
32. Exiqon's new guidelines for microRNA profiling in serum/plasma samples. Available: http://www.exiqon.com/. Accessed 20 February 2013.
33. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.
34. Andersen CL, Jensen JL, Orntoft TF, (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64: 5245-5250.
35. Peltier HJ, Latham GJ, (2008) Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 14: 844-852.
36. Sing T, Sander O, Beerenwinkel N, Lengauer T, (2005) ROCR: visualizing classifier performance in R. Bioinformatics. 21: 3940-3941.
37. Zen K, Zhang CY, (2012) Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 32: 326-348.
38. Wang M, Gu H, Wang S, Qian H, Zhu W, et al. (2012) Ciruculating miR-17-5p and miR-20a: molecular marders for gastric cancer. Mol Med Report 5: 1514-1520.
39. Carlsen AL, Schetter AJ, Nielsen CT, Lood C, Knudsen S, et al. (2013) Circulating microRNA expression profiles associated with systemic lupus erythematosus. Arthritis Rheum. doi: 10.1002/art.37890.
40. Wu L, Zhou H, Lin H, Qi J, Zhu C, et al. (2012) Circulating microRNAs are elevated in plasma from severe preeclamptic pregnancies. Reproduction 143: 389-397.
41. Bai Y, Wang L, Sun L, Ye P, Hui R, (2011) Circulating microRNA-26a: potential predictors and therapeutic targets for non-hypertensive intracerebral hemorrhage. Med Hypotheses 77: 488-490.
42. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Muller SC, et al. (2011) Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 77: 1265.e9-1265.1.
43. Hauser S, Wulfken LM, Holdenrieder S, Moritz R, Ohlmann CH, et al. (2012) Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma. Cancer Epidemiol. Apr: 25.
44. Miyachi M, Tsuchiya K, Yoshida H, Yagyu S, Kikuchi K, et al. (2010) Circulating muscle-specific microRNA, miR-206, as a potential diagnostic marker for rhabdomyosarcoma. Biochem Biophys Res Commun 400: 89-93.
45. Kuwabara Y, Ono K, Horie T, Nishi H, Nagao K, et al. (2011) Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet 4: 446-454.
46. Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, et al. (2010) Serum miR-146a and miR-223 as potential new biomarkers for sepsis. Biochem Biophys Res Commun 394: 184-188.
47. Zhao Z, Zhao Q, Warrick J, Lockwood CM, Woodworth A, et al. (2012) Circulating MicroRNA miR-323-3p as a Biomarker of Ectopic Pregnancy. Clin Chem 58: 896-905.
48. Chim SS, Shing TK, Hung EC, Leung TY, Lau TK, et al. (2008) Detection and characterization of placental microRNAs in maternal plasma. Clin Chem 54: 482-490.
49. Wang H, Tan G, Dong L, Cheng L, Li K, et al. (2012) Circulating MiR-125b as a Marker Predicting Chemoresistance in Breast Cancer. PLoS One 7: e34210.
50. Zhao R, Wu J, Jia W, Gong C, Yu F, et al. (2011) Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy. Onkologie 34: 675-680.
51. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, et al. (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 108: 5003-5008.
52. Kosaka N, Iguchi H, Yoshioka Y, Hagiwara K, Takeshita F, et al. (2012) Competitive interactions of cancer cells and normal cells via secretory microRNAs. J Biol Chem 287: 1397-1405.
53. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, et al. (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9: 654-659.
54. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT, (2011) MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13: 423-433.
55. Luna C, Li G, Qiu J, Epstein DL, Gonzalez P, (2011) MicroRNA-24 regulates the processing of latent TGFbeta1 during cyclic mechanical stress in human trabecular meshwork cells through direct targeting of FURIN. J Cell Physiol 226: 1407-1414.
56. Kim SW, Ramasamy K, Bouamar H, Lin AP, Jiang D, et al. (2012) MicroRNAs miR-125a and miR-125b constitutively activate the NF-kappaB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci U S A 109: 7865-7870.
57. Dons EM, Raimondi G, Cooper DK, Thomson AW, (2012) Induced regulatory T cells: mechanisms of conversion and suppressive potential. Hum Immunol 73: 328-334.
58. Pesu M, Watford WT, Wei L, Xu L, Fuss I, et al. (2008) T-cell-expressed proprotein convertase furin is essential for maintenance of peripheral immune tolerance. Nature 455: 246-250.
59. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, et al. (2010) Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 42: 508-514.
60. Matmati M, Jacques P, Maelfait J, Verheugen E, Kool M, et al. (2011) A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat Genet 43: 908-912.
61. Wang H, Peng W, Ouyang X, Li W, Dai Y, et al. (2012) Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus. Transl Res 160: 198-206.
62. Leidner RS, Li L, Thompson CL, (2013) Dampening enthusiasm for circulating microRNA in breast cancer. PLoS One 8: e57841.